[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma

Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-g...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Weber, Damien C [verfasserIn] Zilli, Thomas Buchegger, Franz Casanova, Nathalie Haller, Guy Rouzaud, Michel Nouet, Philippe Dipasquale, Giovanna Ratib, Osman Zaidi, Habib Vees, Hansjorg Miralbell, Raymond

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2008

Schlagwörter:	Positron Emission Tomotherapy Planning Target Volume Clinical Target Volume Gross Tumor Volume Simultaneous Integrate Boost

Anmerkung:	© Weber et al; licensee BioMed Central Ltd. 2008

Übergeordnetes Werk:	Enthalten in: Radiation oncology - London : BioMed Central, 2006, 3(2008), 1 vom: 24. Dez.
Übergeordnetes Werk:	volume:3 ; year:2008 ; number:1 ; day:24 ; month:12

Links:	Volltext

DOI / URN:	10.1186/1748-717X-3-44

Katalog-ID:	SPR029566320

Internformat


LEADER	01000caa a22002652 4500
001	SPR029566320
003	DE-627
005	20230519230446.0
007	cr uuu---uuuuu
008	201007s2008 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/1748-717X-3-44 \|2 doi
035			\|a (DE-627)SPR029566320
035			\|a (SPR)1748-717X-3-44-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Weber, Damien C \|e verfasserin \|4 aut
245	1	0	\|a [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
264		1	\|c 2008
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Weber et al; licensee BioMed Central Ltd. 2008
520			\|a Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.
650		4	\|a Positron Emission Tomotherapy \|7 (dpeaa)DE-He213
650		4	\|a Planning Target Volume \|7 (dpeaa)DE-He213
650		4	\|a Clinical Target Volume \|7 (dpeaa)DE-He213
650		4	\|a Gross Tumor Volume \|7 (dpeaa)DE-He213
650		4	\|a Simultaneous Integrate Boost \|7 (dpeaa)DE-He213
700	1		\|a Zilli, Thomas \|4 aut
700	1		\|a Buchegger, Franz \|4 aut
700	1		\|a Casanova, Nathalie \|4 aut
700	1		\|a Haller, Guy \|4 aut
700	1		\|a Rouzaud, Michel \|4 aut
700	1		\|a Nouet, Philippe \|4 aut
700	1		\|a Dipasquale, Giovanna \|4 aut
700	1		\|a Ratib, Osman \|4 aut
700	1		\|a Zaidi, Habib \|4 aut
700	1		\|a Vees, Hansjorg \|4 aut
700	1		\|a Miralbell, Raymond \|4 aut
773	0	8	\|i Enthalten in \|t Radiation oncology \|d London : BioMed Central, 2006 \|g 3(2008), 1 vom: 24. Dez. \|w (DE-627)508725739 \|w (DE-600)2224965-5 \|x 1748-717X \|7 nnns
773	1	8	\|g volume:3 \|g year:2008 \|g number:1 \|g day:24 \|g month:12
856	4	0	\|u https://dx.doi.org/10.1186/1748-717X-3-44 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 3 \|j 2008 \|e 1 \|b 24 \|c 12

Indexfelder

author_variant	d c w dc dcw t z tz f b fb n c nc g h gh m r mr p n pn g d gd o r or h z hz h v hv r m rm
matchkey_str	article:1748717X:2008----::8furehlyoieoirnmsinoorpyuddaite
hierarchy_sort_str	2008
publishDate	2008
allfields	10.1186/1748-717X-3-44 doi (DE-627)SPR029566320 (SPR)1748-717X-3-44-e DE-627 ger DE-627 rakwb eng Weber, Damien C verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Weber et al; licensee BioMed Central Ltd. 2008 Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients. Positron Emission Tomotherapy (dpeaa)DE-He213 Planning Target Volume (dpeaa)DE-He213 Clinical Target Volume (dpeaa)DE-He213 Gross Tumor Volume (dpeaa)DE-He213 Simultaneous Integrate Boost (dpeaa)DE-He213 Zilli, Thomas aut Buchegger, Franz aut Casanova, Nathalie aut Haller, Guy aut Rouzaud, Michel aut Nouet, Philippe aut Dipasquale, Giovanna aut Ratib, Osman aut Zaidi, Habib aut Vees, Hansjorg aut Miralbell, Raymond aut Enthalten in Radiation oncology London : BioMed Central, 2006 3(2008), 1 vom: 24. Dez. (DE-627)508725739 (DE-600)2224965-5 1748-717X nnns volume:3 year:2008 number:1 day:24 month:12 https://dx.doi.org/10.1186/1748-717X-3-44 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1 24 12
spelling	10.1186/1748-717X-3-44 doi (DE-627)SPR029566320 (SPR)1748-717X-3-44-e DE-627 ger DE-627 rakwb eng Weber, Damien C verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Weber et al; licensee BioMed Central Ltd. 2008 Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients. Positron Emission Tomotherapy (dpeaa)DE-He213 Planning Target Volume (dpeaa)DE-He213 Clinical Target Volume (dpeaa)DE-He213 Gross Tumor Volume (dpeaa)DE-He213 Simultaneous Integrate Boost (dpeaa)DE-He213 Zilli, Thomas aut Buchegger, Franz aut Casanova, Nathalie aut Haller, Guy aut Rouzaud, Michel aut Nouet, Philippe aut Dipasquale, Giovanna aut Ratib, Osman aut Zaidi, Habib aut Vees, Hansjorg aut Miralbell, Raymond aut Enthalten in Radiation oncology London : BioMed Central, 2006 3(2008), 1 vom: 24. Dez. (DE-627)508725739 (DE-600)2224965-5 1748-717X nnns volume:3 year:2008 number:1 day:24 month:12 https://dx.doi.org/10.1186/1748-717X-3-44 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1 24 12
allfields_unstemmed	10.1186/1748-717X-3-44 doi (DE-627)SPR029566320 (SPR)1748-717X-3-44-e DE-627 ger DE-627 rakwb eng Weber, Damien C verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Weber et al; licensee BioMed Central Ltd. 2008 Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients. Positron Emission Tomotherapy (dpeaa)DE-He213 Planning Target Volume (dpeaa)DE-He213 Clinical Target Volume (dpeaa)DE-He213 Gross Tumor Volume (dpeaa)DE-He213 Simultaneous Integrate Boost (dpeaa)DE-He213 Zilli, Thomas aut Buchegger, Franz aut Casanova, Nathalie aut Haller, Guy aut Rouzaud, Michel aut Nouet, Philippe aut Dipasquale, Giovanna aut Ratib, Osman aut Zaidi, Habib aut Vees, Hansjorg aut Miralbell, Raymond aut Enthalten in Radiation oncology London : BioMed Central, 2006 3(2008), 1 vom: 24. Dez. (DE-627)508725739 (DE-600)2224965-5 1748-717X nnns volume:3 year:2008 number:1 day:24 month:12 https://dx.doi.org/10.1186/1748-717X-3-44 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1 24 12
allfieldsGer	10.1186/1748-717X-3-44 doi (DE-627)SPR029566320 (SPR)1748-717X-3-44-e DE-627 ger DE-627 rakwb eng Weber, Damien C verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Weber et al; licensee BioMed Central Ltd. 2008 Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients. Positron Emission Tomotherapy (dpeaa)DE-He213 Planning Target Volume (dpeaa)DE-He213 Clinical Target Volume (dpeaa)DE-He213 Gross Tumor Volume (dpeaa)DE-He213 Simultaneous Integrate Boost (dpeaa)DE-He213 Zilli, Thomas aut Buchegger, Franz aut Casanova, Nathalie aut Haller, Guy aut Rouzaud, Michel aut Nouet, Philippe aut Dipasquale, Giovanna aut Ratib, Osman aut Zaidi, Habib aut Vees, Hansjorg aut Miralbell, Raymond aut Enthalten in Radiation oncology London : BioMed Central, 2006 3(2008), 1 vom: 24. Dez. (DE-627)508725739 (DE-600)2224965-5 1748-717X nnns volume:3 year:2008 number:1 day:24 month:12 https://dx.doi.org/10.1186/1748-717X-3-44 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1 24 12
allfieldsSound	10.1186/1748-717X-3-44 doi (DE-627)SPR029566320 (SPR)1748-717X-3-44-e DE-627 ger DE-627 rakwb eng Weber, Damien C verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Weber et al; licensee BioMed Central Ltd. 2008 Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients. Positron Emission Tomotherapy (dpeaa)DE-He213 Planning Target Volume (dpeaa)DE-He213 Clinical Target Volume (dpeaa)DE-He213 Gross Tumor Volume (dpeaa)DE-He213 Simultaneous Integrate Boost (dpeaa)DE-He213 Zilli, Thomas aut Buchegger, Franz aut Casanova, Nathalie aut Haller, Guy aut Rouzaud, Michel aut Nouet, Philippe aut Dipasquale, Giovanna aut Ratib, Osman aut Zaidi, Habib aut Vees, Hansjorg aut Miralbell, Raymond aut Enthalten in Radiation oncology London : BioMed Central, 2006 3(2008), 1 vom: 24. Dez. (DE-627)508725739 (DE-600)2224965-5 1748-717X nnns volume:3 year:2008 number:1 day:24 month:12 https://dx.doi.org/10.1186/1748-717X-3-44 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1 24 12
language	English
source	Enthalten in Radiation oncology 3(2008), 1 vom: 24. Dez. volume:3 year:2008 number:1 day:24 month:12
sourceStr	Enthalten in Radiation oncology 3(2008), 1 vom: 24. Dez. volume:3 year:2008 number:1 day:24 month:12
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Positron Emission Tomotherapy Planning Target Volume Clinical Target Volume Gross Tumor Volume Simultaneous Integrate Boost
isfreeaccess_bool	true
container_title	Radiation oncology
authorswithroles_txt_mv	Weber, Damien C @@aut@@ Zilli, Thomas @@aut@@ Buchegger, Franz @@aut@@ Casanova, Nathalie @@aut@@ Haller, Guy @@aut@@ Rouzaud, Michel @@aut@@ Nouet, Philippe @@aut@@ Dipasquale, Giovanna @@aut@@ Ratib, Osman @@aut@@ Zaidi, Habib @@aut@@ Vees, Hansjorg @@aut@@ Miralbell, Raymond @@aut@@
publishDateDaySort_date	2008-12-24T00:00:00Z
hierarchy_top_id	508725739
id	SPR029566320
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR029566320</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519230446.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1748-717X-3-44</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR029566320</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1748-717X-3-44-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Weber, Damien C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Weber et al; licensee BioMed Central Ltd. 2008</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Positron Emission Tomotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Planning Target Volume</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical Target Volume</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gross Tumor Volume</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Simultaneous Integrate Boost</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zilli, Thomas</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buchegger, Franz</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casanova, Nathalie</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haller, Guy</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rouzaud, Michel</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nouet, Philippe</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dipasquale, Giovanna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ratib, Osman</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zaidi, Habib</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vees, Hansjorg</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miralbell, Raymond</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Radiation oncology</subfield><subfield code="d">London : BioMed Central, 2006</subfield><subfield code="g">3(2008), 1 vom: 24. Dez.</subfield><subfield code="w">(DE-627)508725739</subfield><subfield code="w">(DE-600)2224965-5</subfield><subfield code="x">1748-717X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1</subfield><subfield code="g">day:24</subfield><subfield code="g">month:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/1748-717X-3-44</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2008</subfield><subfield code="e">1</subfield><subfield code="b">24</subfield><subfield code="c">12</subfield></datafield></record></collection>
author	Weber, Damien C
spellingShingle	Weber, Damien C misc Positron Emission Tomotherapy misc Planning Target Volume misc Clinical Target Volume misc Gross Tumor Volume misc Simultaneous Integrate Boost [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
authorStr	Weber, Damien C
ppnlink_with_tag_str_mv	@@773@@(DE-627)508725739
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1748-717X
topic_title	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma Positron Emission Tomotherapy (dpeaa)DE-He213 Planning Target Volume (dpeaa)DE-He213 Clinical Target Volume (dpeaa)DE-He213 Gross Tumor Volume (dpeaa)DE-He213 Simultaneous Integrate Boost (dpeaa)DE-He213
topic	misc Positron Emission Tomotherapy misc Planning Target Volume misc Clinical Target Volume misc Gross Tumor Volume misc Simultaneous Integrate Boost
topic_unstemmed	misc Positron Emission Tomotherapy misc Planning Target Volume misc Clinical Target Volume misc Gross Tumor Volume misc Simultaneous Integrate Boost
topic_browse	misc Positron Emission Tomotherapy misc Planning Target Volume misc Clinical Target Volume misc Gross Tumor Volume misc Simultaneous Integrate Boost
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Radiation oncology
hierarchy_parent_id	508725739
hierarchy_top_title	Radiation oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)508725739 (DE-600)2224965-5
title	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
ctrlnum	(DE-627)SPR029566320 (SPR)1748-717X-3-44-e
title_full	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
author_sort	Weber, Damien C
journal	Radiation oncology
journalStr	Radiation oncology
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2008
contenttype_str_mv	txt
author_browse	Weber, Damien C Zilli, Thomas Buchegger, Franz Casanova, Nathalie Haller, Guy Rouzaud, Michel Nouet, Philippe Dipasquale, Giovanna Ratib, Osman Zaidi, Habib Vees, Hansjorg Miralbell, Raymond
container_volume	3
format_se	Elektronische Aufsätze
author-letter	Weber, Damien C
doi_str_mv	10.1186/1748-717X-3-44
title_sort	[(18)f]fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
title_auth	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
abstract	Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients. © Weber et al; licensee BioMed Central Ltd. 2008
abstractGer	Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients. © Weber et al; licensee BioMed Central Ltd. 2008
abstract_unstemmed	Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients. © Weber et al; licensee BioMed Central Ltd. 2008
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
url	https://dx.doi.org/10.1186/1748-717X-3-44
remote_bool	true
author2	Zilli, Thomas Buchegger, Franz Casanova, Nathalie Haller, Guy Rouzaud, Michel Nouet, Philippe Dipasquale, Giovanna Ratib, Osman Zaidi, Habib Vees, Hansjorg Miralbell, Raymond
author2Str	Zilli, Thomas Buchegger, Franz Casanova, Nathalie Haller, Guy Rouzaud, Michel Nouet, Philippe Dipasquale, Giovanna Ratib, Osman Zaidi, Habib Vees, Hansjorg Miralbell, Raymond
ppnlink	508725739
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/1748-717X-3-44
up_date	2024-07-04T01:30:24.711Z
_version_	1803610095314010112
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR029566320</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519230446.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1748-717X-3-44</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR029566320</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1748-717X-3-44-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Weber, Damien C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Weber et al; licensee BioMed Central Ltd. 2008</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on $ T_{1} $-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of 18F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning. Methods Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed. Results Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (p = 0.9), CTVs (mean 57.8 ± 30.4 $ cm^{3} $) were significantly larger than BTVs (mean 42.1 ± 24.4 $ cm^{3} $; p < 0.01) or GTVs (mean 38.7 ± 25.7 $ cm^{3} $; p < 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement. Conclusion Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Positron Emission Tomotherapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Planning Target Volume</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical Target Volume</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gross Tumor Volume</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Simultaneous Integrate Boost</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zilli, Thomas</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buchegger, Franz</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casanova, Nathalie</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Haller, Guy</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rouzaud, Michel</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nouet, Philippe</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dipasquale, Giovanna</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ratib, Osman</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zaidi, Habib</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vees, Hansjorg</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miralbell, Raymond</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Radiation oncology</subfield><subfield code="d">London : BioMed Central, 2006</subfield><subfield code="g">3(2008), 1 vom: 24. Dez.</subfield><subfield code="w">(DE-627)508725739</subfield><subfield code="w">(DE-600)2224965-5</subfield><subfield code="x">1748-717X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1</subfield><subfield code="g">day:24</subfield><subfield code="g">month:12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/1748-717X-3-44</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2008</subfield><subfield code="e">1</subfield><subfield code="b">24</subfield><subfield code="c">12</subfield></datafield></record></collection>
score	7.4006395

Nicht das Richtige dabei?

Schreiben Sie uns!

[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?